SPRC

Scisparc Ltd

Healthcare Biotechnology

Portfolio

Watchlist

0.3848 USD -0.03 ( 8.07%)

Last update at 2026-11-09T15:22:00Z

VOLUME

107117

Market Cap

2.77M

P/E

0.05

Momentum Score

…

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range

0.38

Low

0.44

High

52 Week Price Range

2.98

Low

80.10

High

Momentum Score

…

Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close

0.42

Dividend Yield

Revenue TTM

0.86M

Revenue Per Share

6.89

Gross Profit TTM

0.63M

Debt / Equity

0.09

ROE

-178.39%

Net Debt

-4.22M

ROCE

-233.81%

Diluted EPS TTM

98.07

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-12.56M	-7.49M	-5.86M	-2.58M	-5.79M
Minority interest	0.39M	1.19M	0.76M	0.00M	0.00M
Net income	-12.18M	-6.28M	-5.12M	-2.59M	-5.80M
Selling general administrative	4.72M	4.29M	3.65M	5.38M	3.64M
Selling and marketing expenses	0.72M	1.51M	2.48M	-	-
Gross profit	0.63M	0.51M	2.20M	1.02M	1.07M
Reconciled depreciation	0.23M	0.48M	0.54M	0.19M	0.03M
Ebit	-12.55M	-7.46M	-5.85M	-7.38M	-5.77M
Ebitda	-12.32M	-6.97M	-5.31M	-8.51M	-5.74M
Depreciation and amortization	0.23M	0.48M	0.54M	-1.13M	0.03M
Operating income	-8.75M	-7.32M	-5.77M	-7.38M	-5.77M
Other operating expenses	9.61M	8.62M	8.65M	8.73M	5.77M
Interest expense	0.01M	0.03M	0.01M	0.04M	0.01M
Tax provision	0.00M	-0.01M	0.02M	0.01M	-
Interest income	0.21M	0.42M	0.00M	-	0.00M
Net interest income	1.78M	0.39M	-0.01M	-1.24M	-0.02M
Income tax expense	-	-0.01M	0.02M	0.01M	0.01M
Total revenue	0.86M	1.31M	2.88M	1.35M	1.07M
Total operating expenses	9.38M	7.82M	7.97M	8.40M	5.77M
Cost of revenue	0.23M	0.80M	0.68M	0.32M	-
Total other income expense net	-3.81M	-0.17M	-0.09M	4.80M	-0.02M
Net income from continuing ops	-12.56M	-7.47M	-5.88M	-2.59M	-5.79M
Net income applicable to common shares	-	-	-	-2.59M	-5.79M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	7.62M	10.35M	11.18M	10.61M	9.92M
Intangible assets	-	1.48M	3.19M	-	-
Other current assets	0.11M	0.37M	0.28M	0.10M	0.39M
Total liab	2.48M	1.41M	1.59M	4.16M	1.77M
Total stockholder equity	4.24M	8.15M	7.61M	6.45M	8.14M
Other current liab	1.10M	0.55M	0.72M	2.93M	1.27M
Common stock	76.48M	70.89M	64.53M	58.59M	58.54M
Capital stock	76.48M	70.89M	64.53M	58.59M	58.54M
Retained earnings	-87.15M	-74.97M	-68.69M	-63.57M	-60.98M
Good will	1.17M	-	-	-	-
Cash	4.59M	1.54M	2.14M	3.57M	6.88M
Total current liabilities	2.25M	1.40M	1.57M	4.16M	1.76M
Current deferred revenue	-	-	-	-	-0.15M
Net debt	-4.22M	-1.49M	-2.06M	-3.55M	-6.37M
Short term debt	0.37M	0.04M	0.05M	0.03M	0.49M
Short long term debt	0.36M	-	-	-	0.44M
Short long term debt total	0.37M	0.05M	0.08M	0.03M	0.50M
Other stockholder equity	13.01M	11.75M	0.00M	10.93M	10.08M
Property plant equipment	-	-	-	0.06M	0.09M
Total current assets	5.44M	7.50M	6.45M	4.51M	9.82M
Long term investments	1.00M	1.31M	1.44M	1.32M	-
Net tangible assets	-	-	-	1.73M	8.14M
Short term investments	0.00M	0.52M	3.00M	-	-
Net receivables	0.66M	4.96M	0.29M	0.17M	2.56M
Inventory	0.07M	0.11M	0.74M	0.67M	-
Accounts payable	0.78M	0.82M	0.80M	1.20M	0.15M
Accumulated other comprehensive income	1.91M	0.50M	11.78M	0.50M	0.50M
Non current assets total	2.19M	2.84M	4.74M	6.09M	0.09M
Capital lease obligations	0.01M	0.05M	0.08M	0.03M	0.06M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	0.00M	-1.62M	-1.11M	-7.08M	-0.07M
Change to liabilities	-	-	-	0.00M	0.35M
Total cashflows from investing activities	-1.40M	-1.62M	-1.11M	-7.08M	-0.07M
Net borrowings	4.50M	-0.05M	-0.05M	-0.07M	-0.21M
Total cash from financing activities	8.59M	6.19M	5.50M	11.70M	10.06M
Change to operating activities	-	-	-	0.04M	0.12M
Net income	-12.56M	-7.47M	-5.12M	-2.59M	-5.79M
Change in cash	3.05M	-0.54M	-1.50M	-3.30M	4.93M
Begin period cash flow	1.54M	2.08M	3.57M	6.88M	1.95M
End period cash flow	4.59M	1.54M	2.08M	3.57M	6.88M
Total cash from operating activities	-4.14M	-5.10M	-5.89M	-7.92M	-5.06M
Issuance of capital stock	2.97M	6.25M	5.55M	9.01M	7.70M
Depreciation	0.23M	0.48M	0.54M	0.19M	0.03M
Other cashflows from investing activities	-2.00M	-4.03M	-0.01M	-0.01M	-0.04M
Dividends paid	0.00M	0.00M	0.00M	0.00M	0.00M
Change to inventory	0.04M	0.63M	-0.07M	-0.67M	-0.67M
Change to account receivables	0.79M	-0.52M	-0.35M	-0.08M	0.17M
Other cashflows from financing activities	-0.01M	-0.01M	-0.01M	2.77M	2.57M
Change to netincome	-	-	-	-4.81M	0.05M
Capital expenditures	0.00M	0.00M	0.00M	4.87M	0.04M
Change in working capital	1.45M	0.14M	-0.83M	-0.70M	0.64M
Stock based compensation	1.19M	0.57M	0.20M	0.90M	0.04M
Other non cash items	5.56M	1.18M	-0.67M	-5.71M	0.01M
Free cash flow	-4.14M	-5.10M	-5.89M	-12.79M	-5.10M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
SPRC Scisparc Ltd	-0.03 8.07%	0.38	0.05	-	3.23	0.67	174.58	1.21
NVO Novo Nordisk A/S	0.47 1.18%	40.78	41.58	31.15	2.13	32.99	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	0.34 0.06%	547.43	30.22	24.27	10.36	6.50	9.99	24.66
REGN Regeneron Pharmaceuticals Inc	8.76 0.97%	913.11	29.07	20.12	7.57	3.82	6.95	19.42
ARGNF argenx SE	- -%	900.30	45.77	31.25	13.84	7.12	11.38	36.06

Profile*

Scisparc Ltd

Address

Tower A, Tel Aviv-Yafo, Israel, 6971916

Contact

972 7 334 47180

Website

https://scisparc.com

Employees

Name	Title	Year Born
Mr. Oz Adler C.P.A.	CEO & CFO	1986
Mr. Itschak Shrem	Pres & Director	1947
Dr. Adi Zuloff-Shani Ph.D.	Chief Technologies Officer	1970
Mr. Oz Adler CPA	CEO & CFO	1987
Mr. Itschak Shrem	President & Director	1947
Dr. Adi Zuloff-Shani Ph.D.	Chief Technologies Officer	1969
Mr. Oz Adler C.P.A.	CEO & CFO	1987
Mr. Amitai Weiss	President & Director	1962
Dr. Adi Zuloff-Shani Ph.D.	Chief Technologies Officer	1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

Top Gainers*
Top Losers*

Equity Sectors*

Basic Materials

-1.70%
Communication Services

+0.33%
Consumer Cyclical

+0.45%
Consumer Defensive

-0.56%
Energy

-0.25%
Financial Services

+0.49%
Healthcare

+0.20%
Industrials

+0.74%
Real Estate

+1.71%
Technology

-2.81%
Utilities

+0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

TYT	GBX 3102.38 +3.03%
CPG	GBX 33.81 -1.11%
DGED	GBX 93.25 -1.26%
LTOD	GBX 37.75 -1.44%
KNM	GBX 24500.00 +2.04%

DAR	GBX 8.30 +23.42%
VTY	GBX 276.20 +8.23%
GTCO	GBX 0.09 +6.98%
GLV	GBX 2.34 +6.36%
BUR	GBX 249.20 +5.95%

TMI	GBX 0.72 -6.49%
HSBA	GBX 1291.40 -5.42%
RKT	GBX 5218.00 -4.85%
TGA	GBX 643.00 -4.03%
RKH	GBX 61.70 -3.89%